Oncotarget

Clinical Research Papers:

Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial

Pin Zhang, Yi Yin, Hongnan Mo, Bailin Zhang, Xiang Wang, Qing Li, Peng Yuan, Jiayu Wang, Shan Zheng, Ruigang Cai, Fei Ma, Yin Fan and Binghe Xu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:60647-60656. https://doi.org/10.18632/oncotarget.10607

Metrics: PDF 945 views  |   HTML 1295 views  |   ?  


Abstract

Pin Zhang1,*, Yi Yin2, Hongnan Mo1, Bailin Zhang3, Xiang Wang3, Qing Li1, Peng Yuan1, Jiayu Wang1, Shan Zheng4 , Ruigang Cai1, Fei Ma1, Yin Fan1 and Binghe Xu1,*

1 Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

2 Department of Medical Oncology, Fujian Provincial Cancer Hospital, Fuzhou, China

3 Department of Breast Surgery, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

4 Department of Pathology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

* These authors have contributed equally to the work

Correspondence to:

Binghe Xu, email:

Keywords: breast cancer; triple negative; neoadjuvant chemotherapy; carboplatin; paclitaxel

Received: April 02, 2016 Accepted: June 13, 2016 Published: July 14, 2016

Abstract

Background: No standard chemotherapy is used as neoadjuvant therapy in triple negative breast cancer (TNBC). This study has compared carboplatin plus paclitaxel with commonly used epirubicin plus paclitaxel as neoadjuvant chemotherapy (NAC) in TNBC.

Results: 91 patients with a median age of 47 years (PC 47 patients, EP 44 patients) were enrolled. 65% of the patients were premenopausal. While the objective response rate was similar in the PC and EP arm (89.4% vs. 79.5%, P = 0.195), the pCR rate in the PC arm was significantly higher (38.6% vs. 14.0%, P = 0.014). The median follow-up time was 55.0 months. 5-year RFS were 77.6% and 56.2%, significantly higher in the PC arm, P = 0.043. No significant difference in OS was observed between the two arms (P = 0.350). Adverse events were similar, except for more thrombocytopenia in the PC arm (P = 0.001).

Methods: Patients with stage II/III TNBC were randomized to receive either paclitaxel (175 mg/m2, day1) plus carboplatin (Area Under the Curve = 5, day2) (PC) or epirubicin (75mg/m2, day1) plus paclitaxel (175 mg/m2, day2) (EP) as NAC every three weeks for 4-6 cycles. The primary endpoint was rate of pathologic complete response (pCR).The secondary endpoints included relapse-free survival (RFS), overall survival (OS) and safety.

Conclusions:This study suggested that the addition of carboplatin to paclitaxel was superior to the regimen of epirubicin plus paclitaxel as NAC for TNBC in terms of improving pCR rate and RFS. Further phase 3 study has already started.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10607